For the quarter ending 2025-09-30, RCUS made $26,000K in revenue. -$135,000K in net income. Net profit margin of -519.23%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 26,000 | 160,000 | - | - |
| Research and development (includes 13, (2), 19 and (32) from a related party) | 141,000 | 139,000 | - | - |
| General and administrative (includes 3, , 5, and from a related party) | 27,000 | 29,000 | - | - |
| Impairment of long-lived assets | 0 | 0 | - | - |
| Total operating expenses | 168,000 | 168,000 | - | - |
| Loss from operations | -142,000 | -8,000 | -122,000 | -59,500 |
| Interest and other income, net | 10,000 | 10,000 | 11,000 | 12,500 |
| Interest expense | 3,000 | 2,000 | 1,000 | 1,000 |
| Total non-operating income, net | 7,000 | 8,000 | 10,000 | 11,000 |
| Loss before income taxes | -135,000 | 0 | -112,000 | -48,500 |
| Income tax expense | 0 | 0 | - | 250 |
| Net loss | -135,000 | 0 | -112,000 | -49,000 |
| Basic (in dollars per share) | -1.27 | 0 | -1.14 | -0.56 |
| Basic (in shares) | 106,500,000 | 106,100,000 | 98,400,000 | -46,200,000 |
| Diluted (in dollars per share) | -1.27 | 0 | -1.14 | -0.56 |
| Diluted (in shares) | 106,500,000 | 106,500,000 | 98,400,000 | -46,200,000 |
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)